Hepatitis C virus infection and rituximab therapy after renal transplantation

International Journal of Artificial Organs

Volumn 30, Issue 5, 2007, Pages 445-449

  Fabrizio, Fabrizi ^a   Martin, P ^b   Elli, A ^a   Montagnino, G ^a   Banfi, G ^a   Passerini, P ^a   Campise, M R ^a   Tarantino, A ^a   Ponticelli, C ^a  

^a FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Gastric cancer; Hepatitis C; Renal transplant; Rituximab

Indexed keywords

DISEASES; PATIENT TREATMENT; VIRUSES;

CHRONIC HEPATITIS; GASTRIC CANCERS; HCV RNA; HEPATITIS C; HEPATITIS C VIRUS; RENAL TRANSPLANT RECIPIENTS; RENAL TRANSPLANTATION; RENAL TRANSPLANTS; RITUXIMAB; VIRUS INFECTION;

MONOCLONAL ANTIBODIES;

AMMONIA; BILIRUBIN; CHOLINESTERASE; CORTICOSTEROID; CREATININE; CYCLOSPORIN; GAMMA GLUTAMYLTRANSFERASE; RITUXIMAB; VIRUS RNA;

ADULT; AMMONIA BLOOD LEVEL; ANEMIA; ARTICLE; BACTERIAL PNEUMONIA; BILIRUBIN BLOOD LEVEL; BLOOD TRANSFUSION; CASE REPORT; CAUSE OF DEATH; CHOLESTATIC HEPATITIS; CHOLINESTERASE BLOOD LEVEL; CHRONIC GRAFT REJECTION; CHRONIC HEPATITIS; CREATININE BLOOD LEVEL; DEATH; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG SAFETY; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEPATITIS C; HUMAN; KIDNEY FAILURE; KIDNEY TRANSPLANTATION; LIVER FAILURE; LYMPHOPROLIFERATIVE DISEASE; MULTIPLE CYCLE TREATMENT; POLYMERASE CHAIN REACTION; POSTOPERATIVE PERIOD; RESPIRATORY FAILURE; STOMACH CANCER;

EID: 34447509807     PISSN: 03913988     EISSN: None     Source Type: Journal    
DOI: 10.1177/039139880703000513     Document Type: Article

References (32)

1. Bruchfeld A, Wilczek H, Elinder CG. Hepatitis C infection, time in renal-replacement therapy, and outcome after renal transplantation. Transplantation 2004; 78: 745-50.
2. Stehman-Breen C, Psaty BM, Emerson S, Gretch D, Johnson RJ. Association of hepatitis C virus infection with mortality and graft survival in kidney-pancreas transplant recipients. Transplantation 1997; 64: 281-6.
3. Mazzaro C, Zorat F, Caizzi M, Donada C, Di Gennaro G, Maso LD, et al. Treatment with peg-interferon alfa-2b and ribavirin of hepatitis C virus-associated mixed cryoglobulinemia: a pilot study. J Hepatol 2005; 42: 632-8.
4. Stashenko P, Nadler LM, Hardy R, Schlossman SF. Characterization of a human B-lymphocyte specific antigen. J Immunol 1980; 125: 1678-85.
5. Cheson BD. CHOP plus rituximab. Balancing factors and opinions. N Engl J Med 2002; 346: 280-2.
6. Stasi R, Pagano A, Stipa E, Amadori S. Rituximab chimeric anti-CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpura. Blood 2001; 98: 952-7.
7. Weide R, Heymanns J, Koppler H. Induction of complete haematological remission after monotherapy with anti-CD20 monoclonal antibody (rituximab) in a patient with alkylating agent resistant Waldenstrom's macroglobulinemia. Leuk Lymphoma 1999; 36: 203-6.
8. Zaja F, De Vita S, Mazzaro C, Sacco S, Damaini D, De Marchi G, et al. Efficacy and safety of rituximab in type II mixed cryoglobulinemia. Blood 2003; 101: 3827-34.
9. Sansonno D, De Re V, Lauletta G, Tucci AF, Boiocchi M, Dammacco F. Monoclonal antibody treatment of mixed cryoglobulinemia resistant to interferon-alpha with an anti-CD20. Blood 2003; 101: 3818-26.
10. Lamprecht P, Lerin-Lozano C, Merz H, Dennin RH, Gause A, Voswinkel J, Peters SO, et al. Rituximab induces remission in refractory HCV associated cryoglobulinaemic vasculitis. Ann Rheum Dis 2003; 62: 1230-3.
11. Ghijsels E, Lerut E, Vanrenterghem Y, Kuypers D. Anti-CD20 monoclonal antibody (rituximab) treatment for hepatitis C-negative therapy-resistant essential mixed cryoglobulinemia with renal and cardiac failure. Am J Kidney Dis 2004; 43: E24.
12. Weide R, Heymanns J, Pandorf A, Koppler H. Successful long-term treatment of systemic lupus erythematosus with rituximab maintenance therapy. Lupus 2003; 12: 779-82.
13. Fra GP, Avanzi GC, Bartoli E. Remission of refractory lupus nephritis with a protocol including rituximab. Lupus 2003; 12: 783-7.
14. Ruggenenti P, Chiurchiu C, Brusegan V, Abbate M, Perna A, Filippi C, Remuzzi G. Rituximab in idiopathic membranous nephropathy: a one-year prospective. J Am Soc Nephrol 2003; 14: 1851-7.
15. Quartuccio L, Soardo G, Romano G, Zaja F, Scott CA, De Marchi G, et al. Rituximab treatment for glomerulonephritis in HCV-associated mixed cryoglobulinaemia: efficacy and safety in the absence of steroids. Rheumatology 2006; 1-5.
16. Roccatello D, Baldovino S, Rossi D, Mansouri M, Naretto C, Gennaro M, et al. Long-term effects of anti-CD20 monoclonal antibody treatment of cryoglobulinaemic glomerulonephritis. Nephrol Dial Transplant 2004; 19: 3054-61.
17. Basse G, Ribes D, Kamar N, Mehrenberger M, Esposito L, Guitard J, et al. Rituximab therapy for de novo mixed cryoglobulinemia in renal transplant patients. Transplantation 2005; 80: 1560-4.
18. Davies SE, Portmann BC, O'Grady J, Aldis PM, Chaggar K, Alexander GJ, Williams R. Histological findings after transplantation for chronic hepatitis B infection, including a unique pattern of FCH. Hepatology 1991; 13: 150-7.
19. Lukas K, Kairaritis K, Gottlieb T, George CR. Fatal hepatitis B virus infection with fibrosing cholestatic hepatitis following renal transplantation. Nephrol Dial Transplant 1998; 13: 1571-3.
20. Lam PW, Wachs ME, Somberg KA, Vincent F, Lake JR, Ferrel LD. Fibrosing cholestatic hepatitis in renal transplant recipients. Transplantation 1996; 61: 378-81.
21. Munoz De Bustillo E, Ibarrola C, Colina F, Castellano G, Fuertes A, Andres A, et al. Fibrosing cholestatic hepatitis in hepatitis C virus-infected renal transplant recipients. J Am Soc Nephrol 1998; 9: 1109-13.
22. Zylberberg H, Carnot F, Mamzer MF, Blancho G, Legendre C, Pol S. Hepatitis C virus related fibrosing cholestatic hepatitis after renal transplantation. Transplantation 1997; 63: 158-60.
23. Chisari F, Filippi P, Buras J, McLachlan A, Popper H, Pinkert CA, et al. Structural and pathological effects of synthesis of hepatitis B virus large envelope polypeptide in transgenic mice. Proc Natl Acad Sci USA 1987; 84: 6909-13.
24. Collier J, Heathcote J. Hepatitis C viral infection in the immunosuppressed patient. Hepatology 1998; 27: 2-6.
25. Firpi RJ, Zhu H, Morelli G, Abdelmalek MF, Soldevila-Pico C, Machicao VI, Cabrera R, Reed AI, Liu C, Nelson DR. Cyclosporine suppresses hepatitis C virus in vitro and increases the chance of a sustained virological response after liver transplantation. Liver Transpl 2006; 12: 51-7.
26. Martin P, Busuttil RW, Goldstein RM, Crippin JS, Klintmalm GB, Fitzsimmons WE, Uleman C. Impact of tacrolimus versus cyclosporine in hepatitis C virus-infected liver transplant recipients on recurrent hepatitis: a prospective, randomized trial. Liver Transpl 2004; 10: 1258-62.
27. Straus DJ. HIV-associated lymphoma: promising new results, but with toxicity. Blood 2005; 105: 1842.
28. Ng HJ, Lim LC. Fulminant hepatitis B virus reactivation with concomitant listeriosis after fludarabine and rituximab therapy: case report. Ann Hematol 2001; 80: 549-52.
29. Sharma VR, Fleming DR, Slone SP. Pure red cell aplasia due to parvovirus B19 in a patient treated with rituximab. Blood 2000; 96: 1184-6.
30. Bermudez A, Marco F, Conde E, Mazo E, Recio M, Zubizarreta A. Fatal visceral varicella-zoster following rituximab and chemotherapy treatment in a patient with follicular lymphoma. Haematologica 2000; 85: 894-5.
31. Aksoy S, Abali H, Kilickap S, Erman M, Kars A. Accelerated hepatitis C virus replication with rituximab treatment in a non-Hodgkin's lymphoma patient. Clin Lab Haem 2006; 28: 211-4.
32. Genberg H, Hansson A, Wernerson A, Wennberg L, Tyden G. Pharmacodynamics of rituximab in kidney allotransplantation. Am J Transplant 2006; 6: 2418-28.